CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 2.36 HKD 2.61% Market Closed
Market Cap: 3B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CStone Pharmaceuticals
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Operating Income
-ÂĄ307.9m
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-ÂĄ1.1B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ4.3B
CAGR 3-Years
-27%
CAGR 5-Years
11%
CAGR 10-Years
42%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
2.93 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Operating Income?
Operating Income
-307.9m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Operating Income amounts to -307.9m CNY.

What is CStone Pharmaceuticals's Operating Income growth rate?
Operating Income CAGR 5Y
21%

Over the last year, the Operating Income growth was 60%. The average annual Operating Income growth rates for CStone Pharmaceuticals have been 34% over the past three years , 21% over the past five years .

Back to Top